PICCOLO trial met its primary endpoint of objective response rate (ORR)
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Revolutionary ovarian cancer rapid test available Q4 2022
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
But acquisition charges drag earnings into loss
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Subscribe To Our Newsletter & Stay Updated
